Option chain shows key data for scPharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for scPharmaceuticals.

scPharmaceuticals (NASDAQ:SCPH) Stock, Option Chain

scPharmaceuticals

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Equities

News

Health Care

Financing

Offerings

Movers

Trading Ideas

General

SCPH

FDA approves scPharmaceuticals&#39; expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuticals secures $125M non-dilutive financing to repay debt and advance commercialization. SCP-111 PK study shows 107.3% bioavailability, with favorable safety outcomes.

Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization

Penny Stocks

Short Ideas

Small Cap

NVAX

NVTA

OMER

SAVA

STOK

TARS

TLRY

As of the close of business on Wednesday, 6/28, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector.

The average short interest for stocks within the Healthcare sector stands at 3.48%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

Short Interest Sector Focus: Healthcare Sector

BDTX

SENS

As of the close of business on Tuesday, 6/27, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector.

The average short interest for stocks within the Healthcare sector stands at 3.51%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

scPharmaceuticals Inc

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">235.8000</td>
<td align="right">1.330</td>
<td align="right">0.56</td>
<td>16.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">227.3000</td>
<td align="right">1.250</td>
<td align="right">0.55</td>
<td>165</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">40.5711</td>
<td align="right">0.221</td>
<td align="right">0.54</td>
<td>258</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">84.2300</td>
<td align="right">0.430</td>
<td align="right">0.51</td>
<td>519</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.0000</td>
<td align="right">0.240</td>
<td align="right">0.31</td>
<td>5.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.4000</td>
<td align="right">0.120</td>
<td align="right">0.24</td>
<td>25.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.7400</td>
<td align="right">0.190</td>
<td align="right">0.22</td>
<td>4.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">78.5000</td>
<td align="right">0.130</td>
<td align="right">0.16</td>
<td>468</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">137.4703</td>
<td align="right">0.230</td>
<td align="right">0.16</td>
<td>1.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">132.1200</td>
<td align="right">0.200</td>
<td align="right">0.15</td>
<td>984</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 31, 2024

CVKD

Cadrenal Therapeutics Looks Ahead To 2025 And Initiation Of Pivotal Phase 3 Clinical Trial For Tecarfarin In Left Ventricular Assist Devices

Keefe, Bruyette &amp; Woods analyst Catherine Mealor reiterates Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) with a Outperform and maintains $45 price target.

Price Target

Reiteration

Analyst Ratings

RNST

Keefe, Bruyette & Woods Reiterates Outperform on Renasant, Maintains $45 Price Target

"We recently presented very exciting data at the San Antonio Breast Cancer meeting highlighting synergistic activity between a novel combination of paxalisib and immunotherapy, and we believe paxalisib shows potential to be evaluated in breast cancers where iPI3K pathway mutations are known to drive tumor growth. The Kazia team, in conjunction with the Board of Directors, is continuing to evaluate several options, and we expect to provide an outline for our path forward to maximize shareholder value by the end of January 2025," the company said.

KZIA

Kazia Says It Evaluates Next Steps In NDU Glioblastoma;  Believes Paxalisib Shows Potential To Be Evaluated In Breast Cancers

Stifel analyst Thomas Stephan maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $153 to $175.

GKOS

Stifel Maintains Buy on Glaukos, Raises Price Target to $175

Following discussions with the FDA and feedback from Kazia's recent Type C meeting, the FDA's current position is that data on OS would generally not be appropriate for accelerated approval, but could be considered to support a traditional/standard approval.&nbsp;
The Agency further commented that the secondary endpoint OS data from the GBM-AGILE study are supportive and informative for designing and executing a pivotal registrational study in pursuit of a standard approval.
&nbsp;Importantly, the Company aligned with the FDA on key aspects of the design of a proposed registrational/pivotal phase 3 study, including patient population, primary endpoint, and the comparator arm to be used.

Kazia Therapeutics Updates On Paxalisib Regulatory Pathway Following Type C Meeting With FDA; Says FDA's Current Position Is That Data On OS Would Generally Not Be Appropriate For Accelerated Approval

Stifel analyst Stephen Gengaro downgrades Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) from Buy to Hold and lowers the price target from $4.5 to $0.5.

Downgrades

GOEV

Stifel Downgrades Canoo to Hold, Lowers Price Target to $0.5

"While CC-42344 showed a favorable safety and tolerability profile, we're disappointed by the low infectivity rate of the challenge influenza strain used in this study. The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules. The low infectivity obtained in this study hindered antiviral data analysis," said Sam Lee, Ph.D., Cocrystal's President and co-CEO.

COCP

Cocrystal Pharma Plans To Extend Phase 2a Influenza Challenge Study With Oral PB2 Inhibitor CC-42344 Due To Low Influenza Infection Among Challenged Participants

FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares are trading higher premarket on Tuesday. On Monday, the company launched a strategic capital initiative in <a href="https://www.benzinga.com/pressreleases/24/12/g42733059/ftai-aviation-launches-strategic-capital-initiative-and-announces-2025-financial-guidance">partnership with institutional investors.</a>
The first partnership under the initiative will focus on acquiring 737NG and A320ceo aircraft and this market opportunity will allow for the deployment of&nbsp;over $3.0 billion of capital annually.
This initiative and partnerships will allow FTAI to maintain an asset-light model while the partnerships actively acquire on-lease narrowbody aircraft at scale.
As part of this initiative, FTAI has agreed to sell 46 on-lease narrowbody aircraft to the partnership for a net purchase price of $549 million.
All engines within the partnership will utilize FTAI&#8217;s Maintenance, Repair, and Exchange services.
Outlook: FTAI expects adjusted EBITDA from its reportable segments of <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$1.1 billion to $1.15 billion for FY25</a>.
This includes around $500 million from Aviation Leasing and $600 to $650 million from Aerospace Products.
The company&#8217;s key assumptions include producing an average of 100 modules per quarter at the Montreal facility, maintaining or improving net Aerospace margins from 2024, and completing 25 to 35 V2500 engine MRE transactions in 2025.
As of September 30, 2024, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41636318/ftai-aviation-ltd-reports-third-quarter-2024-results-declares-dividend-of-0-30-per-ordinary-share" rel="noreferrer noopener">cash and equivalents of $111.9 million</a>.
Investors can gain exposure to the stock via Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF (GABF) and Invesco Dorsey Wright Financial Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFI#NASDAQ">PFI</a>).
Price Action: FTAI shares are up 5.92% at $134.00 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42737644" target="_blank" rel="noreferrer noopener">US Stocks Poised To Open Higher On Last Trading Day Of 2024: Analyst Sees S&amp;P 500 At 7,000 In First Half Of 2025</a></li>
</ul>
Image via Shutterstock.

Large Cap

Guidance

Asset Sales

FTAI

PowerShares Dynamic Financial Sector Portfolio

Why Is FTAI Aviation Stock Surging Today?

As we look ahead to 2025, the technology landscape appears poised for transformation with several highly anticipated releases from industry giants.
From novel AR experiences to next-generation gaming and computing power, here&#8217;s what might shape our digital future.
Samsung&#8217;s Vision For Everyday AR
A leak this year suggested that Samsung Electronic Co&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) would leverage its partnerships with Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google and Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) to develop AI-powered smart glasses.
The device could be potentially similar to Meta Platforms, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) collaboration with Ray-Ban.
These glasses could feature advanced micro-LED displays, eye-tracking, and gesture controls. Samsung reportedly plans an initial production run of approximately 500,000 units, with a targeted release window in the third quarter of 2025.
See Also: <a href="https://www.benzinga.com/24/12/42384578/iphone-charging-cables-arent-all-safe-how-hackers-turn-them-into-tools-of-espionage">Not All iPhone Charging Cables Are Safe: Here&#8217;s How Hackers Turned Them Into Tools Of Espionage</a>
Nintendo Switch 2: Evolution Of Hybrid Gaming
Nintendo ADR&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) anticipated Switch successor looks to build upon the foundation of its predecessor. The reported 8-inch display reportedly offers a more immersive handheld experience, while magnetic Joy-Cons may provide better durability and responsiveness.
Moreover, Nintendo&#8217;s commitment to backward compatibility could reportedly ensure a smooth transition for its extensive user base. The hybrid nature of the console continues to distinguish Nintendo in the gaming market.
Apple M5 MacBook Pro: Pushing Performance Boundaries
Apple Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) silicon journey continues with the rumored M5 chip, potentially marking another leap forward in mobile computing. While maintaining the proven design language of current MacBooks, the M5 processor could introduce architectural improvements that further separate Apple from traditional x86-based competitors.
Expected improvements in machine learning capabilities and power efficiency might enable new workflows previously impractical on portable devices.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Amazon's Finally Upgraded Alexa
Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) reportedly plans to overhaul its Alexa smart assistant in 2025, integrating generative AI for smarter, more intuitive voice commands.
The upgraded voice assistant, revealed in September 2023, was slated for release this year. It promises ChatGPT-like intelligence and more fluid, conversational exchanges.
However, a November report stated, "Alexa AI teams were recently told that their target deadline had been moved into 2025."
Apple iPad (11th Gen): Speed Boost Incoming&nbsp;
Apple is likely to launch the 11th generation of its iconic iPad in 2025. The new device will reportedly maintain a design similar to the 2022 version while offering a significant speed boost.
It&#8217;s rumored to feature either the A16 chip from the iPhone 15 or possibly an upgrade to the A17 or A18. This new iPad promises improved performance and efficiency, building on its predecessors.
With these exciting gadgets, 2025 is shaping up to be a year of major technological breakthroughs.
Photo Courtesy: Bird stocker TH On Shutterstock.com
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41061167/ios-18-includes-apples-new-passwords-app-with-end-to-end-encryption-heres-how-you-use-it">iOS 18 Includes Apple's New Passwords App with End-to-End Encryption: Here's How You Use It</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Tech

AAPL

AMZN

GOOG

GOOGL

NTDOY

QCOM

SSNLF

Apple, Amazon, Samsung, And Nintendo: What Tech Marvels Are These Giants Cooking In 2025

As 2024 winds down, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is holding steady near its key 20-day averages. Meanwhile, Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is poised for a potential rebound, above its 50-day average.
What Happened: The technical health of these stocks can be assessed by identifying support and resistance levels, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
<h3 class="wp-block-heading">Nvidia Corp</h3>
The technical analysis of daily moving averages indicates that the stock is clinging to the support provided by its 20-day exponential moving average.
The stock ended at $137.49 apiece on Monday. This was just above its 21-day exponential moving average of $137.36 and 20-day simple moving average of $137.37. However, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, its current stock price was lower than the 50-day simple moving average of $139.96 and higher than its 200-day simple moving average of $117.63.
This implies that the stock is taking support at 20-day levels and the relative strength index of 49.91 suggests the stock&#8217;s movement is in the neutral zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-1024x576.png" alt="" class="wp-image-713223" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071547/Nvidia-Tech-Chart-fin-fin.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<h3 class="wp-block-heading">Meta Platforms</h3>
The technical analysis of daily moving averages indicates a bullish uptrend as the stock has moved past its 50-day moving average levels.
The stock ended at $591.24 apiece on Monday. This was above its 50-day simple moving average of $587.91 and 50-day exponential moving average of $588.93. However, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, its current stock price was lower than the 20-day simple moving average of $609.59, and above its 200-day moving average of $528.11.
This implies that the stock is in an uptrend. On the other hand, the relative strength index of 46.5 suggests the stock&#8217;s movement is in the neutral zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-1024x576.png" alt="" class="wp-image-713225" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31071651/Meta-Tech-Chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Why It Matters: As we head into the new year, Jim Cramer in an X post dated Dec.16, warned of a potential market correction for Nvidia on X, citing its recent surge and lack of a "crescendo moment." He predicted a "vicious" and "fast" reversal. This comes as Nvidia faces an antitrust investigation in China over its 2020 acquisition of Mellanox Technologies.
TF Securities analyst Ming-Chi Kuo expects the investigation to remain unresolved in the near term, drawing parallels to Qualcomm Inc‘s QCOM 15-month antitrust case in China.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42720866/bond-vigilantes-send-loud-warning-message-as-treasuries-climb-to-may-highs-is-the-santa-rally-in-serious-doubt-heres-what-analysts-say">Bond Vigilantes Send &#8216;Loud Warning Message&#8217; As Treasuries Climb To May Highs: Is The Santa Rally In &#8216;Serious Doubt&#8217;? Here&#8217;s What Analysts Say</a> 
JPMorgan raised Meta Platforms&#8217; price target to $725, maintaining its &#8220;overweight&#8221; rating on Dec. 1. The firm anticipates robust internet sector growth in 2025, driven by a shift in AI focus towards applications and agents. It expects increased AI spending next year from Meta and other tech leaders as they overcome 2024&#8217;s compute constraints.
Truist Securities analyst Youssef Squali maintained a &#8216;buy&#8217; rating on Meta and bumped the target price to $700 per share based on the company&#8217;s strong revenue, gross profit margin, and sustained growth potential.
Price Action: Shares of Nvidia are up 0.62% in premarket and 185.43% on a year-to-date basis, outperforming the Nasdaq 100, which was up 28.13% over the year.
According to Benzinga, Nvidia has a consensus price target of $170.56 based on the ratings of 40 analysts. The highest price target out of all the analysts <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">tracked</a> by Benzinga is $220 issued by Rosenblatt as of Nov. 21, 2024. The lowest target price is $120 issued by New Street Research on Aug. 6, 2024.
The average price target of $154.67 between DA Davidson, Phillip Securities, and Truist Securities implies an 11.83% upside for Nvidia.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/NVDA/analyst-ratings"><img loading="lazy" decoding="async" width="940" height="349" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070718/NVDA-ANR.png" alt="" class="wp-image-713213" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070718/NVDA-ANR.png 940w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070718/NVDA-ANR-300x111.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070718/NVDA-ANR-768x285.png 768w" sizes="(max-width: 940px) 100vw, 940px" /></a></figure>
See Also: <a href="https://www.benzinga.com/markets/24/12/42732351/chamath-palihapitiya-says-s-p-500-index-etfs-need-to-be-fixed-or-they-will-end-in-disaster-here-is-w">Chamath Palihapitiya Says S&amp;P 500 index ETFs Need To Be &#8216;Fixed&#8217; Or They Will End In &#8216;Disaster&#8217; — Here Is What The Billionaire Investor Said</a> 
Shares of Meta are up 0.48% in premarket and 70.74% on a year-to-date basis, outperforming the Nasdaq 100, which was up 28.13% over the year.
According to Benzinga, Meta has a consensus price target of $642.51 based on the ratings of 41 analysts. The highest price target out of all the analysts <a href="https://www.benzinga.com/quote/META/analyst-ratings">tracked</a> by Benzinga is $811 issued by Rosenblatt as of Oct. 31. The lowest target price is $360 issued by Exane BNP Paribas on May 2.
The average price target of $154.67 between JPMorgan, Truist Securities, and Piper Sandler implies a 17.55 upside for Meta.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/META/analyst-ratings"><img loading="lazy" decoding="async" width="942" height="357" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070319/Meta-ANR-.png" alt="" class="wp-image-713212" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070319/Meta-ANR-.png 942w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070319/Meta-ANR--300x114.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31070319/Meta-ANR--768x291.png 768w" sizes="(max-width: 942px) 100vw, 942px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42721523/apples%20chinese-rival-huawei-slashes-prices-for-new-year-boost-should-tim-cook-led-company-be-worried-heres-what-analysts-are-saying-about-aapl-stock">Apple&#8217;s Chinese Rival Huawei Slashes Prices For New Year Boost: Should Tim Cook-Led Company Be Worried? Here&#8217;s What Analysts Are Saying About AAPL Stock</a> </li>
</ul>
Image via Shutterstock

Market Summary

Technicals

Markets

NVDA

Nvidia Defends Key Support As This Magnificent 7 Peer Approaches Buy Zone: Here's What Technical Analysis Says

SpaceX CEO Elon Musk said on Tuesday that the launch provider will probably carry about 99% of Earth&#8217;s payload to orbit in 2026. 
What Happened: In spite of other companies in the field of space travel growing, SpaceX will still probably launch about 99% of Earth&#8217;s payload to orbit in 2026, Musk said in a post on X. 
&#8220;Assuming rocket launches by competitors grow at their current rate, SpaceX will probably do 99.9% of payload to orbit in 10 years, but I hope I'm wrong,&#8221; the billionaire CEO said while adding that it would be &#8220;better&#8221; if rival organizations too rose up to meet his aim of taking humans to the surface of Earth&#8217;s neighboring planet Mars. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Let's not get carried away! SpaceX will probably do ~99% of Earth payload to orbit in 2026, despite the rest of industry growing. Assuming rocket launches by competitors grow at their current rate, SpaceX will probably do 99.9% of payload to orbit in 10 years, but I hope I'm…
&mdash; Kekius Maximus (@elonmusk) <a href="https://twitter.com/elonmusk/status/1873938728957428021?ref_src=twsrc%5Etfw">December 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to a report from Bryce Tech, SpaceX launched about 362,087 kg of spacecraft upmass in the third quarter followed by China Aerospace Science and Technology Corporation (CASC) with about 30,350 kg. While Spacex launched 518 spacecraft in the three months, CASC launched just 56. 
Why It Matters: In September, Musk said that SpaceX will launch <a href="https://www.benzinga.com/news/24/09/41022762/elon-musk-adjusts-forecast-on-spacexs-share-of-all-mass-to-orbit-if-the-rest-of-the-year-goes-well">close to 90% of all mass to orbit in 2024</a>, trumping the competition by a huge margin.
"If the rest of the year goes well, SpaceX will launch close to 90% of all mass to orbit. China will be ~6% and rest of world ~4%," Musk wrote on social media platform X.
SpaceX has completed<a href="https://www.benzinga.com/general/space/24/12/42717337/spacex-kicks-off-post-christmas-operations-with-double-launch-eyes-134-missions-in-2024"> 134 launches thus far</a> this year, not including four Starship test flights, marking a significant milestone. For the entirety of 2023, SpaceX only completed 96 launches, not including two test flights of the company&#8217;s Starship launch vehicle.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/12/42717337/spacex-kicks-off-post-christmas-operations-with-double-launch-eyes-134-missions-in-2024" target="_blank" rel="noreferrer noopener">SpaceX Kicks Off Post-Christmas Operations With Double Launch, Eyes 134 Missions In 2024</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

Elon Musk Sees SpaceX Carrying About 99% Of Earth's Payload To Orbit In 2026

GTLS

Chart Industries Received The Order From Bechtel For The Supply Of Our Integrated Pre-cooled Single Mixed Refrigerant  Liquefaction Technology And Cold Boxes For Phase 1 Of Woodside Energy Group's Louisiana LNG Development Opportunity

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) from Buy to Buy.

AXSM

HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy

Cheniere Energy Achieves Their First Liquefied Natural Gas (LNG) Production From The First Train Of The Cheniere's Corpus Christi Stage 3 Liquefaction Project On December 30

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">Kimbell Royalty Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>)</h3>
<ul>
<li>Dividend Yield: 10.21%</li>
<li>Truist Securities analyst Neal Dingmann maintained a Buy rating and cut the price target from $23 to $21 on Sept. 30. This analyst has an accuracy rate of 66%.</li>
<li>Raymond James analyst John Freeman maintained a Strong Buy rating and cut the price target from $22 to $20 on Jan. 24. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: Kimbell Royalty Partners will release its fourth quarter financial results on Thursday, Feb. 27, 2025, before the opening bell.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1">latest KRP news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043413/image-239.png" alt="" class="wp-image-713038" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043413/image-239.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043413/image-239-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043413/image-239-768x709.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">HF Sinclair Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>)</h3>
<ul>
<li>Dividend Yield: 5.84%</li>
<li>Wells Fargo analyst Roger Read downgraded the stock from Overweight to Equal-Weight and cut the price target from $53 to $45 on Dec. 9. This analyst has an accuracy rate of 63%.</li>
<li>Barclays analyst Theresa Chen maintained an Equal-Weight rating and cut the price target from $44 to $42 on Nov. 11. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On Oct. 31, HF Sinclair reported a third-quarter revenue decline of 19% year over year to $7.207 billion, beating the consensus of $6.833 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1">latest DINO new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="921" height="722" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043503/image-240.png" alt="" class="wp-image-713041" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043503/image-240.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043503/image-240-300x235.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043503/image-240-768x602.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</h3>
<ul>
<li>Dividend Yield: 4.46%</li>
<li>Wells Fargo analyst Roger Read downgraded the stock from Overweight to Equal-Weight and slashed the price target from $42 to $25 on Dec. 17. This analyst has an accuracy rate of 63%.</li>
<li>Citigroup analyst Scott Gruber maintained a Neutral rating and lowered the price target from $29 to $24 on Nov. 26. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Dec. 23, APA announced the pricing terms of cash tender offers for certain series of outstanding Apache Corporation notes.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in APA<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"> stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent123124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043546/image-241.png" alt="" class="wp-image-713044" style="width:701px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043546/image-241.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043546/image-241-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/31043546/image-241-768x703.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Dividends

DINO

Wall Street's Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 4% Dividend Yields

HC Wainwright &amp; Co. analyst Scott Buck maintains Arqit Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) with a Buy and raises the price target from $27 to $52.

ARQQ

HC Wainwright & Co. Maintains Buy on Arqit Quantum, Raises Price Target to $52

Tesla Inc. CEO Elon Musk changed his name on his social media platform, X, to "Kekius Maximus" (CRYPTO: KEKIUS). He also changed his profile picture to that of &#8220;Pepe the Frog&#8221; as the year 2024 draws to a close.
What Happened: Musk changing his name on X to Kekius Maximus sent the memecoin of the same name soaring more than 600% over the past 24 hours, according to data from <a href="http://pro.benzinga.com">Benzinga Pro.</a>
Musk changing his profile picture to Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) also sent the coin soaring – it was up by more than 7% at the time of writing.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42735623/trump-backed-platforms-pick-years-chart-topper-6-new-cryptos-added-to-grayscales-top-20-list-with-growth-potential-in-q1-2025">Trump-Backed Platform&#8217;s Pick, Year&#8217;s Chart Topper: 6 New Cryptos Added To Grayscale&#8217;s &#8216;Top 20&#8217; List With Growth Potential In Q1 2025</a>
This is not the first time Musk has changed his profile picture or name to that of a memecoin.
Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), a well-known meme coin, has often been a favorite of Musk. On several occasions, Musk has embraced memes by changing his profile name or picture. He once updated the display picture of Twitter&#8217;s (now X) official account to feature a Shiba Inu dog, the iconic symbol of Dogecoin.
Benzinga Note: Investing in meme coins and cryptocurrencies is highly speculative and involves significant risk. Meme coins often lack intrinsic value and are driven by market sentiment, social media trends, and speculative trading. Prices can be extremely volatile, and you may lose your entire investment. Always conduct thorough research, assess your risk tolerance, and consult with a financial advisor before investing in cryptocurrencies or meme coins.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42738817/new-year-new-strategy-buy-crypto-like-you-buy-fine-wine-in-2025-experts-share-resolutions">New Year, New Strategy: Buy Crypto Like You Buy Fine Wine In 2025 — Experts Share Resolutions</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

Elon Musk Changes His Name To 'Kekius Maximus' On X, Sending This Memecoin Skyrocketing Over 600%

VRME: 253% &#x7C; <a href="https://www.benzinga.com//node/42733494">VerifyMe, Inc.: Stedham Adam H (Director, CEO and President) Buys 22,000 @ Avg Price: $0.71 (Form4)</a>
&nbsp;
NXU: 82% &#x7C; <a href="https://www.benzinga.com//node/42733027">Nxu Inc. files to sell 114.5M shares of Class A common stock for holders</a>
&nbsp;
SGMO: -64% &#x7C; <a href="https://www.benzinga.com//node/42733316">Sangamo Therapeutics Reveals Pfizer's Decision To Terminate Global Collaboration And License Agreement Between The Parties; Sangamo To Regain Full Rights to Hemophilia A Gene Therapy Program</a>
&nbsp;
&nbsp;

SGMO

VRME

Market-Moving News for December 31st

Despite a 30% decline over the last 30 days, Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) continues to see rising burn rates, prompting traders to focus on its <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42715583/shiba-inu-burn-rate-soars-dogecoin-whales-on-a-buying-spree-and-more-this-week-in-crypto#:~:text=Shiba%20Inu%20Burn%20Rate%20Skyrockets,potential%20price%20rebound%20or%20reversal.">critical support levels</a>.    
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002116&nbsp;</td>
<td>$12.5 billion</td>
<td>-2.1%</td>
<td>-5.1%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.319</td>
<td>$47 billion</td>
<td>-0.5%</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001958</td>
<td>$8.2 billion</td>
<td>+5.6%</td>
<td>+7.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto chart analyst Ali Martinez highlighted SHIB's significant support zone between $0.0000215 and $0.0000193. 
A trader responding to the post suggested that if these levels hold, SHIB could see a potential bounce.
However, the ongoing bearish momentum increases the risk of breaking below this range. 
The trader recommended patience and strategic entries for those considering positions.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/ShibaInu?src=hash&amp;ref_src=twsrc%5Etfw">#ShibaInu</a> <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> most significant support zone is between $0.0000215 and $0.0000193! <a href="https://t.co/wgaEbvI96K">pic.twitter.com/wgaEbvI96K</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1874006326591853020?ref_src=twsrc%5Etfw">December 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Benzinga's technical analysis shows SHIB's RSI at 20, signaling oversold conditions and indicating a potential buy signal.
Statistics: According to Shibburn, 1.72 million SHIB were burned in the last 24 hours, with approximately 1 million SHIB burned in a single transaction six hours ago, pushing the burn rate up by 243.3%.
IntoTheBlock data shows a 1.6% decline in SHIB whale transactions, while daily active addresses remained steady at 15.5 billion. Daily transactions on Shibarium rose from 4.6 million to 4.7 million, reflecting consistent activity on the network.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42692745/shiba-inu-burn-rate-spikes-2227-whats-going-on">Shiba Inu Burn Rate Spikes 2,227%: What&#8217;s Going On?</a></li>
</ul>
Image: Shutterstock

$SHIB

'Dogecoin Killer' Shiba Inu Burn Rate Surges 243%: What Is Going On?

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on scPharmaceuticals (SCPH – Research Report). The compan...

Craig-Hallum Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)

scPharmaceuticals GAAP EPS of -$0.75 misses by $0.45, revenue of $10.02M misses by $0.78M

Reports Q3 revenue $3.8M, consensus $10.8M. "The continued growth of FUROSCIX net revenue is encouraging, particularly as we have begun to see incr...

scPharmaceuticals reports Q3 EPS (41c), consensus (30c)

scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript

TD Cowen analyst Stacy Ku maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) yesterday and set a price target of $25.00. Stacy K...

Positive Buy Rating for scPharmaceuticals Driven by Strong Furoscix Launch and Strategic Growth Initiatives

Craig-Hallum lowered the firm's price target on scPharmaceuticals (SCPH) to $12 from $16 and keeps a Buy rating on the shares. The firm notes the c...

scPharmaceuticals price target lowered to $12 from $16 at Craig-Hallum

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alcon (ALC – Research Report), Innate Pharma SA (I...

Analysts Conflicted on These Healthcare Names: Alcon (ALC), Innate Pharma SA (OtherIPHYF) and scPharmaceuticals (SCPH)

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on scPharmaceuticals (SCPH – Research Report) and keeping the price target at $20.00. N...

Positive Outlook for scPharmaceuticals: Strategic Growth and Regulatory Milestones Drive Buy Rating

Craig-Hallum analyst Chase Knickerbocker assigned a Buy rating to the stock today. The company's shares closed yesterday at $3.61. According to Tip...

Craig-Hallum Issues a Buy Rating on scPharmaceuticals (SCPH)

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on scPharmaceuticals (SCPH – Research Report), with a price target of $2...

Comments

scPharmaceuticals

scPharmaceuticals (SCPH) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga